Five years of clinical experience with metronomic chemotherapy: Achievements and perspectives

[1] Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (22) : 3623 - 3628

[2] Browder T, 2000, CANCER RES, V60, P1878

[3] High-dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma [J]. CLINICAL CANCER RESEARCH, 2006, 12 (17) : 5190 - 5198

[4] Burstein HJ, 2005, BREAST CANCER RES TR, V94, pS6

[5] Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer:: antitumor activity and biological effects [J]. ANNALS OF ONCOLOGY, 2006, 17 (02) : 232 - 238

[6] Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer:: antitumor activity and correlation with vascular endothelial growth factor levels [J]. ANNALS OF ONCOLOGY, 2002, 13 (01) : 73 - 80

[7] Angiogenesis as a therapeutic target [J]. NATURE, 2005, 438 (7070) : 967 - 974

[8] GARCIA AA, 2007, IN PRESS J CLIN ONCO

[9] Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (05) : 641 - 648

[10] Gille Jens, 2005, J Dtsch Dermatol Ges, V3, P26, DOI 10.1046/j.1439-0353.2005.04048.x

[1] Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (22) : 3623 - 3628

[2] Browder T, 2000, CANCER RES, V60, P1878

[3] High-dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma [J]. CLINICAL CANCER RESEARCH, 2006, 12 (17) : 5190 - 5198

[4] Burstein HJ, 2005, BREAST CANCER RES TR, V94, pS6

[5] Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer:: antitumor activity and biological effects [J]. ANNALS OF ONCOLOGY, 2006, 17 (02) : 232 - 238

[6] Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer:: antitumor activity and correlation with vascular endothelial growth factor levels [J]. ANNALS OF ONCOLOGY, 2002, 13 (01) : 73 - 80

[7] Angiogenesis as a therapeutic target [J]. NATURE, 2005, 438 (7070) : 967 - 974

[8] GARCIA AA, 2007, IN PRESS J CLIN ONCO

[9] Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (05) : 641 - 648

[10] Gille Jens, 2005, J Dtsch Dermatol Ges, V3, P26, DOI 10.1046/j.1439-0353.2005.04048.x